Eye Tracking Proof of Concept (Pigio™)
Our patented eye-tracking technology was first embodied as Gaze-to-Speech™ to help voiceless patients communicate using only eye movements. It launched as an iOS App called Pigio™ ICU, allowing Intensive Care Unit patients (conscious but intubated or paralyzed) to communicate through eye movements. By gazing at a particular image for a few seconds on the tablet’s screen, its content is activated, and the chosen audible message is heard. The Pigio™ Pro version includes additional features and screens including media & entertainment access to news, YouTube, and Facebook. With a growing number of downloads and uses each day, Pigio™ users have allowed us to improve the performance of our eye-tracking technology to a level that is comparable or better than existing infrared solutions. Pigio™ is easily accessible and free for basic use. You can download it from your iPad here. Besides spreading the message that AI can do good, anonymous Pigio™ users are helping our machine & deep learning technology power our future regulated Software-as-a-Medical-Device (SaMD) offerings. We are currently building a pipeline of clinical trials to support this SaMD portfolio.
Multiple Sclerosis (CIS/RRMS)
Innodem, in partnership with the Montreal NEURO and a pharmaceutical giant, is currently conducting a multiyear clinical trial with patients suffering from the early stages of MS (Clinically Isolated Syndrome or CIS & Relapsing-Remitting Multiple Sclerosis or RRMS). Our EMB & GMB technologies are used to measure at what point the transition from CIS to RRMS occurs relative to the gold standard EDSS (Expanded Disability Status Scale).
Multiple Sclerosis (RRMS/SPMS)
Innodem, in partnership with the Montreal NEURO and another pharmaceutical giant, are planning a multi-year clinical trial with patients suffering from MS. Our EMB & GMB technologies will be applied to track disease progression and change in cognition, in addition to assessing response to treatment relative to the gold standard EDSS (Expanded Disability Status Scale).
Cancer-Related Cognitive Impairment
Innodem, in partnership with the CHUM have begun a clinical trial with cancer patients to monitor patient cognitive function and improve patient quality of life using our EMB and GMB technologies.
Parkinson’s Disease & Progressive Supranuclear Palsy
Innodem, in partnership with the Montreal NEURO, are planning a clinical trial with PD & PSP patients to assist with the difficult differential diagnosis of these patient populations using our EMB & GMB technologies. The inclusion of PSP patients can contaminate the results of promising pharmaceutical clinical trials targeting Parkinson’s.
Amyotrophic Lateral Sclerosis
Innodem, in partnership with the Montreal NEURO, are planning a clinical trial with ALS patients to monitor disease progression using our EMB & GMB technologies. This trial is scheduled for 2021.
Our EMB & GMB technologies are intended to improve the efficiency of most neuro-related clinical trials in the pharmaceutical industry. It has been architected into two modules:
The downloadable mobile App (Front end)
Enrolled patients can download our App from home to an iPad. The App itself consists of a short, interactive, intuitive video that walks the patient through a series of visual tasks to perform (taking about 15 min to complete). The tasks are designed to measure EMBs and GMBs for the assessment of disease-specific cognitive functions (memory, attention, executive functions, speed of information processing, visual-spatial abilities, etc.). Remote testing, even during a pandemic, can be conducted daily, weekly, or monthly depending on the trial.
The machine & deep learning infrastructure (Back end)
Our App works offline but when it is online, it connects to our HIPAA and PIPEDA compliant data platform on the Cloud where EMBs & GMBs are processed anonymously by our machine & deep learning algorithms. The latter are disease-specific and trained on cumulative data that includes healthy controls.